Regeneron Pharmaceuticals Competitors

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Amgen, as reported by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Amgen has a consensus price target of $261.0476, suggesting a potential upside of 2.09%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Amgen's revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Amgen on 9 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Gilead Sciences has a consensus price target of $97.92, suggesting a potential upside of 46.43%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Gilead Sciences' revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Gilead Sciences on 9 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Vertex Pharmaceuticals has a consensus price target of $293.1250, suggesting a potential upside of 33.61%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Biogen's revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Regeneron Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Biogen, as reported by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Biogen has a consensus price target of $303.5862, suggesting a potential upside of 12.31%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Biogen.

Summary

Regeneron Pharmaceuticals beats Biogen on 9 of the 15 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher earnings, but lower revenue than Regeneron Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Alexion Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Alexion Pharmaceuticals presently has a consensus target price of $153.4286, suggesting a potential downside of 6.26%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.58%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Alexion Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Seagen and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Seagen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Seagen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Seagen and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Seagen presently has a consensus target price of $185.3571, suggesting a potential upside of 27.39%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.58%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Seagen.

Summary

Regeneron Pharmaceuticals beats Seagen on 9 of the 14 factors compared between the two stocks.